Zevra therapeutics reports fourth quarter and full year 2023 financial results and corporate updates

Launch of olpruva® underway topline results from kp1077 phase 2 study demonstrate clinically meaningful benefits for key ih symptoms q4 2023 net revenue of $13.2m, and fy 2023 net revenue of $27.5m conference call scheduled for today, march 28, 2024, at 4:30 p.m. et  celebration, fla.
ZVRA Ratings Summary
ZVRA Quant Ranking